Moving beyond cytotoxic drug dosing in ovarian cancer.

Eskander, Ramez N; Monk, Bradley J

Eskander, Ramez N; Monk, Bradley J.

Afiliação

Eskander RN; Division of Gynecologic Oncology and Center for Personalized Cancer Therapy, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Diego, Moores Comprehensive Cancer Center, La Jolla, CA 92093, USA. Electronic address: reskander@ucsd.edu.
Monk BJ; Division of Gynecologic Oncology and Center for Personalized Cancer Therapy, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Diego, Moores Comprehensive Cancer Center, La Jolla, CA 92093, USA.

Lancet ; 394(10214): 2043-2045, 2019 12 07.

Article em En | MEDLINE | ID: mdl-31791687

Assuntos

Antineoplásicos; Carcinoma; Neoplasias Ovarianas; Animais; Tubas Uterinas; Feminino; Humanos; Intervalo Livre de Progressão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma / Antineoplásicos Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google